Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market

 Published On: Dec, 2011 |  Published By: GBI Research | Format: PDF
Request Free Sample

The leading business intelligence provider, has released its latest research “Monoclonal Antibodies Market to 2017- Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market” which provides insights about monoclonal antibodies sales forecasts until 2017. Monoclonal antibodies markets in the key geographies of the US, Europe and the Rest of The World are also covered in the report. The report also includes details about monoclonal antibodies R&D pipelines and potential future blockbuster products. The report provides in-depth analysis of therapeutic indication, which includes HER2 Breast Cancer, Bone Metastases and Bone Loss Due to Cancer Therapy, Relapsing-remitting Multiple Sclerosis (RRMS), Metastatic Non-Small Cell Lung Cancer (NSCLC) and Rheumatoid Arthritis. Furthermore, it includes market forecasts for each of the covered therapeutic indications. The report also explores the competitive landscape with a competitive analysis of the top companies in the market. GBI Research analysis estimated the global monoclonal antibodies market to be valued at $15.6 billion in 2010, with a compound annual growth rate (CAGR) of 36.7% between 2002 and 2010. The market is forecast to grow at a CAGR of 10.6% between 2010 and 2017 and to reach $31.7billion by 2017. In-depth analysis in the report is based on propriety databases, primary and secondary research and in–house analysis by the GBI Research team of experts. GBI Research analysis found the R&D pipeline for the monoclonal antibodies market to be moderate. Many of the major pharmaceutical companies such as Roche, Amgen, and Johnson & Johnson are expanding into this market. This indicates that monoclonal antibodies R&D activity will remain active for at least the next four to five years.


Scope

  • Data and analysis of the monoclonal antibodies market in the leading geographies of the world: the US and Europe. The indications treated by different classes of MAbs discussed, which are covered in this report are in breast cancer, bone loss & metastasis, RRMS, NSCLC and rheumatoid arthritis.
  • Annualized market data for the monoclonal antibodies market from 2002 to 2010, with forecasts to 2017.
  • Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and sales volumes
  • Key drivers and restraints that have had significant impact on the market.
  • Competitive landscape of the global monoclonal antibodies market including benchmarking of the top companies. The key companies analysed in this report are Hoffman La Roche, Amgen, Abbott, Johnson & Johnson, Novartis, Biogen Idec, Merck, Eli Lilly

Reasons to Buy

  • Build effective strategies to launch pipeline products, by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products to fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of the top competitors.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety.


1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Monoclonal Antibodies Market to 2017: Executive Summary

2.1 Monoclonal Antibodies are the Largest Class of Biotherapeutic Drugs

2.2 Successful MAbs such as Rituxan, Avastin and Remicade have Received Regulatory Approvals for Multiple Indications, which Further Increased the Patient Base

2.3 Enormous Market Size for MAbs in Diseases Associated With Genetic Mutations Such As Oncology and Autoimmune Diseases

3 Monoclonal Antibodies Market to 2017: Introduction

3.1 GBI Research Report Guidance

4 Monoclonal Antibodies Market to 2017: Market Characterization

4.1 Introduction

4.1.1 Stability in the Body

4.1.2 Systemic Cancer Treatment

4.1.3 Targeted Therapy

4.2 Monoclonal Antibody Technology

4.2.1 Hybridoma Technology

4.2.2 FuCell Technology

4.3 Revenue Forecasts – Global

4.3.1 Prescription Population

4.3.2 Annual Cost of Therapy

4.3.3 Revenue

4.4 Revenue Forecasts – Countrywise

4.4.1 US

4.4.2 Europe

4.4.3 Rest of the World (ROW)

4.5 Treatment Usage Patterns

4.5.1 The US

4.5.2 Europe

4.5.3 ROW

4.6 Annual Cost of Therapy

4.6.1 The US

4.6.2 Europe

4.6.3 ROW

4.7 Global MAbs Trends

4.7.1 Market Trends

4.7.2 Technology Trends

4.8 Product Trends

4.8.1 Research and Development Focus Shifted Towards Humanized and Fully Human MAbs

4.9 Global MAbs Market Drivers

4.9.1 Gradual Growth in the Uptake of MAbs Have Driven the Monoclonal Antibody Sales Growth

4.9.2 Improved Side-effect Profiles and Tolerance of MAbs Therapy

4.9.3 Lack of Effective Conventional Therapies Accelerates Utilization of MAbs

4.9.4 Expanded Indications Opens up New Potential Patient Groups

4.9.5 Lack of Generics Augmented the Sales Growth of MAbs

4.10 Global MAbs Market Restraints

4.10.1 High Cost of MAbs Hampering the Growth of Treatment Population

4.10.2 Adverse Effects – Generation of Antibodies against MAbs in Patients Receiving Monoclonal Antibody Therapy

4.10.3 Industry Challenges – Majority of MAbs Receive Approvals as Last Option Therapies

4.11 Unmet Needs

4.11.1 Reduction in High Cost of MAb Therapies is the Major Unmet Need and it is also Responsible for Low Utilization by Patients

4.11.2 MAbs Do Not Cure Diseases; They either Treat Signs and Symptoms or Decelerate Cell Proliferation

5 Monoclonal Antibodies Market to 2017: Breast Cancer (Adjuvant and Metastatic)

5.1 Overview

5.2 Introduction

5.3 Prescription Population

5.3.1 Global

5.3.2 The US

5.3.3 Europe

5.3.4 ROW

5.4 Annual Cost of Therapy

5.4.1 Global

5.4.2 The US

5.4.3 Europe

5.4.4 ROW

5.5 Market Size

5.5.1 The US

5.5.2 Europe

5.5.3 ROW

5.6 Marketed Products

5.6.1 Herceptin (trastuzumab)

5.7 Pipeline Analysis

5.7.1 Phase lll

5.7.2 Phase ll

5.7.3 Phase l

5.7.4 Preclinical/Discovery

5.8 Promising Molecules

5.8.1 Pertuzumab (2C4, trade name Omnitarg)

5.8.2 Ramucirumab (IMC-1121B)

6 MAbs Market Size in Bone Metastases and Bone Loss Due to Cancer Therapy

6.1 Introduction

6.2 Epidemiology

6.3 Diagnosis

6.4 Treatment

6.5 Prescription Population

6.5.1 Global

6.5.2 The US

6.5.3 Europe

6.5.4 ROW

6.6 Annual Cost of Therapy

6.6.1 Global

6.6.2 The US

6.6.3 Europe

6.6.4 ROW

6.7 Market Size

6.7.1 Global

6.7.2 The US

6.7.3 Europe

6.7.4 ROW

6.8 Marketed Products

6.8.1 Xgeva (denosumab)

6.9 Pipeline Analysis

6.9.1 NDA Filed

6.9.2 Phase ll

6.9.3 Phase l

6.9.4 Preclinical/Discovery

7 MAbs Market Size in Relapsing-Remitting Multiple Sclerosis (RRMS)

7.1 Introduction

7.2 Epidemiology

7.3 Diagnosis

7.4 Treatment

7.5 Prescription Population

7.5.1 Global

7.5.2 The US

7.5.3 Europe

7.5.4 ROW

7.6 Annual Cost of Therapy

7.6.1 Global

7.6.2 The US

7.6.3 Europe

7.6.4 ROW

7.7 Market Size

7.7.1 Global

7.7.2 The US

7.7.3 Europe

7.7.4 ROW

7.8 Marketed Products

7.8.1 Description

7.8.2 Mechanism of Action

7.8.3 Indications and Usage

7.8.4 Dosage

7.9 Pipeline Analysis

7.9.1 Phase lll

7.9.2 Phase ll

7.9.3 Phase l

7.9.4 Preclinical/Discovery

7.10 Promising Molecules

7.10.1 Campath (Alemtuzumab)

7.10.2 Ocrelizumab

8 MAbs Market Size in Metastatic Non-Small Cell Lung Cancer (NSCLC)

8.1 Introduction

8.2 Epidemiology

8.3 Diagnosis

8.4 Prescription Population

8.4.1 Global

8.4.2 The US

8.4.3 Europe

8.4.4 ROW

8.5 Annual Cost of Therapy

8.5.1 Global

8.5.2 The US

8.5.3 Europe

8.5.4 ROW

8.6 Market Size

8.6.1 Global

8.6.2 The US

8.6.3 Europe

8.6.4 ROW

8.7 Marketed Products

8.7.1 Avastin

8.8 Pipeline Analysis

8.8.1 Phase III

8.8.2 Phase II

8.8.3 Phase I

8.9 Promising Molecule

8.9.1 Necitimumab

8.9.2 Ramucirumab

9 Monoclonal Antibodies Market to 2017 - Rheumatoid Arthritis

9.1 Introduction

9.2 Epidemiology

9.3 Diagnosis

9.4 Treatment

9.5 Prescription Population

9.5.1 Global

9.5.2 The US

9.5.3 Europe

9.5.4 ROW

9.6 Annual Cost of Therapy

9.6.1 Global

9.6.2 The US

9.6.3 Europe

9.6.4 ROW

9.7 Market Size

9.7.1 Global

9.7.2 The US

9.7.3 Europe

9.7.4 ROW

9.8 Marketed Products

9.8.1 Rituxan

9.8.2 Remicade

9.8.3 Humira

9.8.4 Cimzia

9.8.5 Simponi

9.8.6 Actemra

9.9 Pipeline Analysis

9.9.1 Phase III

9.9.2 Phase II

9.9.3 Phase I

9.9.4 Preclinical/ Discovery Phase

9.10 Promising Molecule

9.10.1 Ofatumumab (Arzerra)

9.10.2 SAR153191(REGN88)

10 Monoclonal Antibodies Market to 2017: Competitive Landscape

10.1 Market Share Analysis

10.1.1 Major Companies

10.2 Amgen Inc

10.2.1 Company Profile

10.2.2 Marketed Products

10.2.3 SWOT Analysis

10.3 Abbott Laboratories

10.3.1 Company Profile

10.3.2 Marketed Products

10.3.3 SWOT Analysis

10.4 Johnson & Johnson

10.4.1 Company Profile

10.4.2 Marketed Products

10.4.3 SWOT Analysis

10.5 Novartis AG

10.5.1 Company Profile

10.5.2 Marketed Products

10.5.3 SWOT Analysis

10.6 Biogen Idec

10.6.1 Company Profile

10.6.2 Marketed Products

10.6.3 SWOT Analysis

10.7 Merck & Co Inc

10.7.1 Company Profile

10.7.2 Marketed Products

10.7.3 SWOT Analysis

10.8 Eli Lilly and Company

10.8.1 Company Profile

10.8.2 Marketed Products

10.8.3 SWOT Analysis

10.9 Roche

10.9.1 Company Profile

10.9.2 Marketed Products

10.9.3 SWOT Analysis

11 Monoclonal Antibodies Market to 2017: Strategic Consolidations

11.1 Deal Type

11.2 Mergers & Acquisitions

11.2.1 By Geography

11.2.2 M&A by Year

11.2.3 M&A by Value

11.2.4 Top M&A Deals

11.3 Licensing Agreement

11.3.1 By Geography

11.3.2 By Year

11.3.3 By Value

11.3.4 Licensing Agreement Deals by Value

11.3.5 Top Five Licensing Deals

11.4 Partnerships

11.4.1 By Geography

11.4.2 By Year

11.4.3 By Value

12 Monoclonal Antibodies Market to 2017: Appendix

12.1 Market Definitions

12.2 Abbreviations

12.3 Research Methodology

12.3.1 Coverage

12.3.2 Secondary Research

12.3.3 Primary Research

12.3.4 Therapeutic Landscape

12.3.5 Geographical Landscape

12.3.6 Pipeline Analysis

12.3.7 Competitive Landscape

12.3.8 Expert Panel Validation

12.4 Contact Us

12.5 Disclaimer

12.6 Sources

List of Figures

Figure 1: Monoclonal Antibodies Market, Global, MAbs Share in Global Biologics Therapeutics Market (%), 2011

Figure 2: Monoclonal Antibodies Market, Global, Sales of MAbs Among Top 10 Biologic Therapeutic Molecules ($bn), 2010

Figure 3: Monoclonal Antibodies Market, Global, Drivers and Barriers, 2011

Figure 4: Monoclonal Antibodies Market, Global, Prescription Population (thousands), 2002-2017

Figure 5: Monoclonal Antibodies Market, Global, Annual Cost of Therapy ($), 2002-2017

Figure 6: Monoclonal Antibodies Market, Global, Revenue Forecasts ($bn), 2002-2017

Figure 7: Monoclonal Antibodies Market, Global, The US, Revenue Forecasts ($bn), 2002-2017

Figure 8: Monoclonal Antibodies Market, Global, Europe, Revenue Forecasts ($bn), 2002-2017

Figure 9: Monoclonal Antibodies Market, Global, ROW, Revenue Forecasts ($bn), 2002-2017

Figure 10: Monoclonal Antibodies Market, Global,The US, Prescription Population, 2002- 2017

Figure 11: Monoclonal Antibodies Market, Global,Europe, Prescription Population, 2002- 2017

Figure 12: Monoclonal Antibodies Market, Global, ROW, Prescription Population, 2002- 2017

Figure 13: Monoclonal Antibodies Market, Global, The US, Annual Cost of Therapy ($), 2002- 2017

Figure 14: Monoclonal Antibodies Market, Global, Europe, Annual Cost of Therapy ($), 2002- 2017

Figure 15: Monoclonal Antibodies Market, Global, ROW, Annual Cost of Therapy ($), 2002- 2017

Figure 16: Monoclonal Antibodies Market, Global, Revenue Distibution by Indication (%), 2011

Figure 17: Monoclonal Antibodies Market, Breast Cancer,Global, Prescription Population, 2002- 2017

Figure 18: Monoclonal Antibodies Market, Breast Cancer, the US, Prescription Population, 2002- 2017

Figure 19: Monoclonal Antibodies Market, Breast Cancer,Europe, Prescription Population, 2002- 2017

Figure 20: Monoclonal Antibodies Market, Breast Cancer, ROW, Prescription Population, 2002- 2017

Figure 21: Monoclonal Antibodies Market, Breast Cancer, Global, Annual Cost of Therapy ($), 2002- 2017

Figure 22: Monoclonal Antibodies Market, Breast Cancer,The US, Annual Cost of Therapy ($), 2002- 2017

Figure 23: Monoclonal Antibodies Market, Breast Cancer, Europe, Annual Cost of Therapy ($), 2002- 2017

Figure 24: Monoclonal Antibodies Market, Breast Cancer, ROW, Annual Cost of Therapy ($), 2002- 2017

Figure 25: Monoclonal Antibodies Market, Breast Cancer, Global, Revenue Forecasts ($bn), 2002- 2017

Figure 26: Monoclonal Antibodies Market, Breast Cancer,The US, Revenue Forecasts ($bn), 2002- 2017

Figure 27: Monoclonal Antibodies Market, Breast Cancer,Europe, Revenue Forecasts ($bn), 2002- 2017

Figure 28: Monoclonal Antibodies Market, Breast Cancer, ROW, Revenue Forecasts ($bn), 2002- 2017

Figure 29: Monoclonal Antibodies Market, HER2 Breast Cancer, Pipeline Analysis (%), 2011

Figure 30: Monoclonal Antibodies Market, Bone Metastasis, Global, Prescription Population, 2011- 2017

Figure 31: Monoclonal Antibodies Market, Bone Metastasis, the US, Prescription Population, 2011- 2017

Figure 32: Monoclonal Antibodies Market, Bone Metastasis, Europe, Prescription Population, 2011- 2017

Figure 33: Monoclonal Antibodies Market, Bone Metastasis, ROW, Prescription Population, 2011- 2017

Figure 34: Monoclonal Antibodies Market, Bone Metastasis, Global, Annual Cost of Therapy ($), 2011- 2017

Figure 35: Monoclonal Antibodies Market, Bone Metastasis,The US, Annual Cost of Therapy ($), 2011- 2017

Figure 36: Monoclonal Antibodies Market, Bone Metastasis,Europe, Annual Cost of Therapy, 2011- 2017

Figure 37: Monoclonal Antibodies Market, Bone Metastasis, ROW, Annual Cost of Therapy ($), 2011- 2017

Figure 38: Monoclonal Antibodies Market, Bone Metastasis, Global, Revenue Forecasts ($bn), 2011- 2017

Figure 39: Monoclonal Antibodies Market, Bone Metastasis,The US, Revenue Forecasts ($m), 2011- 2017

Figure 40: Monoclonal Antibodies Market, Bone Metastasis,Europe, Revenue Forecasts ($m), 2011- 2017

Figure 41: Monoclonal Antibodies Market, Bone Metastasis, ROW, Revenue Forecasts ($m), 2011- 2017

Figure 42: Monoclonal Antibodies Market, RRMS, Global, Prescription Population, 2006- 2017

Figure 43: Monoclonal Antibodies Market, RRMS,The US, Prescription Population, 2006- 2017

Figure 44: Monoclonal Antibodies Market, RRMS,Europe, Prescription Population, 2006- 2017

Figure 45: Monoclonal Antibodies Market, RRMS, ROW, Prescription Population, 2009- 2017

Figure 46: Monoclonal Antibodies Market, RRMS, Global, Annual Cost of Therapy ($), 2006- 2017

Figure 47: Monoclonal Antibodies Market, RRMS,The US, Annual Cost of Therapy ($), 2006- 2017

Figure 48: Monoclonal Antibodies Market, RRMS, Europe, Annual Cost of Therapy ($), 2006- 2017

Figure 49: Monoclonal Antibodies Market, RRMS, ROW, Annual Cost of Therapy ($), 2006- 2017

Figure 50: Monoclonal Antibodies Market, RRMS, Global, Revenue Forecasts ($bn), 2006- 2017

Figure 51: Monoclonal Antibodies Market, RRMS,The US, Revenue Forecasts ($m), 2006- 2017

Figure 52: Monoclonal Antibodies Market, RRMS,Europe, Revenue Forecasts ($m), 2006- 2017

Figure 53: Monoclonal Antibodies Market, RRMS, ROW, Revenue Forecasts ($m), 2009- 2017

Figure 54: Monoclonal Antibodies Market, RRMS, Pipeline Analysis, (%), 2011

Figure 55: Monoclonal Antibodies Market, NSCLC, Global, Prescription Population, 2007- 2017

Figure 56: Monoclonal Antibodies Market, NSCLC, The US, Prescription Population, 2007- 2017

Figure 57: Monoclonal Antibodies Market, NSCLC, Europe, Prescription Population, 2008- 2017

Figure 58: Monoclonal Antibodies Market, NSCLC, ROW, Prescription Population, 2007 2017

Figure 59: Monoclonal Antibodies Market, NSCLC, Global, Annual Cost of Therapy ($), 2007- 2017

Figure 60: Monoclonal Antibodies Market, NSCLC, The US, Annual Cost of Therapy ($), 2007- 2017

Figure 61: Monoclonal Antibodies Market, NSCLC, Europe, Annual Cost of Therapy ($), 2008- 2017

Figure 62: Monoclonal Antibodies Market, NSCLC, ROW, Annual Cost of Therapy ($), 2007- 2017

Figure 63: Monoclonal Antibodies Market, NSCLC, Global, Revenue Forecasts ($bn), 2007- 2017

Figure 64: Monoclonal Antibodies Market, NSCLC, The US, Revenue Forecasts ($bn), 2007- 2017

Figure 65: Monoclonal Antibodies Market, NSCLC, Europe, Revenue Forecasts ($million), 2008- 2017

Figure 66: Monoclonal Antibodies Market, NSCLC, ROW, Revenue Forecasts ($m), 2007- 2017

Figure 67: Monoclonal Antibodies Market, NSCLC, Pipeline Analysis, (%), 2011

Figure 68: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Prescription Population, 2002- 2017

Figure 69: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Prescription Population, 2002- 2017

Figure 70: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Prescription Population, 2002- 2017

Figure 71: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Prescription Population, 2002- 2017

Figure 72: Monoclonal Antibodies Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2002- 2017

Figure 73: Monoclonal Antibodies Market, Rheumatoid Arthritis, The US, Annual Cost of Therapy ($), 2002- 2017

Figure 74: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Annual Cost of Therapy ($), 2002- 2017

Figure 75: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Annual Cost of Therapy ($), 2002- 2017

Figure 76: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Revenue Forecasts ($bn), 2002- 2017

Figure 77: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Revenue Forecasts ($bn), 2002- 2017

Figure 78: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Revenue Forecasts ($bn), 2002- 2017

Figure 79: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Revenue Forecasts ($bn), 2002- 2017

Figure 80: Monoclonal Antibodies Market, Rheumatoid Arthritis, Pipeline Analysis, (%), 2011

Figure 81: Monoclonal Antibodies Market to 2017, Global, Market share Analysis by Company (%), 2010

Figure 82: Monoclonal Antibodies Market to 2017, Amgen Inc SWOT Analysis, 2011

Figure 83: Monoclonal Antibodies Market to 2017, Abbott Laboratories SWOT Analysis, 2011

Figure 84: Monoclonal Antibodies Market to 2017, Johnson & Johnson SWOT Analysis, 2011

Figure 85: Monoclonal Antibodies Market to 2017, Novartis AG SWOT Analysis, 2011

Figure 86: Monoclonal Antibodies Market to 2017, Biogen Idec SWOT Analysis, 2011

Figure 87: Monoclonal Antibodies Market to 2017, Merck & Co Inc SWOT Analysis, 2011

Figure 88: Monoclonal Antibodies Market to 2017, Eli Lilly and Company SWOT Analysis, 2011

Figure 89: Monoclonal Antibodies Market to 2017, Roche SWOT Analysis, 2011

Figure 90: Monoclonal Antibodies Market, Strategic Consolidations, Analysis by Deal Type, 2010-2011

Figure 91: Monoclonal Antibodies Market, Strategic Consolidations, M&A, Analysis by Geography, 2011

Figure 92: Monoclonal Antibodies Market, Strategic Consolidations, M&A, Analysis by Year, 2011

Figure 93: Monoclonal Antibodies Market, Strategic Consolidations, M&A, Analysis by Value, 2011

Figure 94: Monoclonal Antibodies Market, Strategic Consolidations, Licensing Agreement, Analysis by Geography, 2011

Figure 95: Monoclonal Antibodies Market, Strategic Consolidations, Licensing Agreement, Analysis by Year, 2011

Figure 96: Monoclonal Antibodies Market, Strategic Consolidations, Licensing Agreement, Analysis by Value, 2011

Figure 97: Monoclonal Antibodies Market, Strategic Consolidations, Partnerships, Analysis by Geography, 2011

Figure 98: Monoclonal Antibodies Market, Strategic Consolidations, Partnerships, Analysis by Year, 2011

Figure 99: Monoclonal Antibodies Market, Strategic Consolidations, Partnerships, Analysis by Value, 2011

Figure 100: GBI Research Market Forecasting Model

List of Tables

Table 1: Monoclonal Antibodies Market, Global, Prescription Population (thousands), 2002-2010

Table 2: Monoclonal Antibodies Market, Global, Prescription Population, 2010-2017

Table 3: Monoclonal Antibodies Market, Global, Annual Cost of Therapy ($), 2002-2010

Table 4: Monoclonal Antibodies Market, Global, Annual Cost of Therapy ($), 2010-2017

Table 5: Monoclonal Antibodies Market, Global, Revenue ($bn), 2002-2010

Table 6: Monoclonal Antibodies Market, Global, Revenue Forecasts ($bn), 2010-2017

Table 7: Monoclonal Antibodies Market, Global, The US, Revenue ($bn), 2002-2010

Table 8: Monoclonal Antibodies Market, Global, The US, Revenue Forecasts ($bn), 2010-2017

Table 9: Monoclonal Antibodies Market, Global, Europe, Revenue ($bn), 2002-2010

Table 10: Monoclonal Antibodies Market, Global, Europe, Revenue Forecasts ($bn), 2010-2017

Table 11: Monoclonal Antibodies Market, Global, ROW, Revenue ($bn), 2002-2010

Table 12: Monoclonal Antibodies Market, Global, ROW, Revenue Forecasts ($bn), 2010-2017

Table 13: Monoclonal Antibodies Market, Global,The US, Prescription Population, 2002- 2010

Table 14: Monoclonal Antibodies Market, Global,The US, Prescription Population, 2010- 2017

Table 15: Monoclonal Antibodies Market, Global,Europe, Prescription Population, 2002- 2010

Table 16: Monoclonal Antibodies Market, Global,Europe, Prescription Population, 2010- 2017

Table 17: Monoclonal Antibodies Market, Global, ROW, Prescription Population, 2002- 2010

Table 18: Monoclonal Antibodies Market, Global, ROW, Prescription Population, 2010- 2017

Table 19: Monoclonal Antibodies Market, Global, The US, Annual Cost of Therapy ($), 2002- 2010

Table 20: Monoclonal Antibodies Market, Global, The US, Annual Cost of Therapy ($), 2010- 2017

Table 21: Monoclonal Antibodies Market, Global, Europe, Annual Cost of Therapy ($), 2002- 2010

Table 22: Monoclonal Antibodies Market, Global, Europe, Annual Cost of Therapy ($), 2010- 2017

Table 23: Monoclonal Antibodies Market, Global, ROW, Annual Cost of Therapy ($), 2002- 2010

Table 24: Monoclonal Antibodies Market, Global, ROW, Annual Cost of Therapy ($), 2010- 2017

Table 25: Monoclonal Antibodies Market, Breast Cancer, Global, Prescription Population, 2002- 2010

Table 26: Monoclonal Antibodies Market, Breast Cancer, Global, Prescription Population, 2010- 2017

Table 27: Monoclonal Antibodies Market, Breast Cancer, the US, Prescription Population, 2002- 2010

Table 28: Monoclonal Antibodies Market, Breast Cancer, the US, Prescription Population, 2010- 2017

Table 29: Monoclonal Antibodies Market, Breast Cancer,Europe, Prescription Population, 2002- 2010

Table 30: Monoclonal Antibodies Market, Breast Cancer,Europe, Prescription Population, 2010- 2017

Table 31: Monoclonal Antibodies Market, Breast Cancer, ROW, Prescription Population, 2002- 2010

Table 32: Monoclonal Antibodies Market, Breast Cancer, ROW, Prescription Population, 2010- 2017

Table 33: Monoclonal Antibodies Market, Breast Cancer, Global, Annual Cost of Therapy ($), 2002- 2010

Table 34: Monoclonal Antibodies Market, Breast Cancer, Global, Annual Cost of Therapy ($), 2010- 2017

Table 35: Monoclonal Antibodies Market, Breast Cancer,The US, Annual Cost of Therapy ($), 2002- 2010

Table 36: Monoclonal Antibodies Market, Breast Cancer,The US, Annual Cost of Therapy ($), 2010- 2017

Table 37: Monoclonal Antibodies Market, Breast Cancer, Europe, Annual Cost of Therapy ($), 2002- 2010

Table 38: Monoclonal Antibodies Market, Breast Cancer, Europe, Annual Cost of Therapy ($), 2010- 2017

Table 39: Monoclonal Antibodies Market, Breast Cancer, ROW, Annual Cost of Therapy ($), 2002- 2010

Table 40: Monoclonal Antibodies Market, Breast Cancer, ROW, Annual Cost of Therapy ($), 2010- 2017

Table 41: Monoclonal Antibodies Market, Breast Cancer, Global, Revenue ($bn), 2002- 2010

Table 42: Monoclonal Antibodies Market, Breast Cancer, Global, Revenue Forecasts ($bn), 2010- 2017

Table 43: Monoclonal Antibodies Market, Breast Cancer,The US, Revenue ($bn), 2002- 2010

Table 44: Monoclonal Antibodies Market, Breast Cancer,The US, Revenue Forecasts ($bn), 2010- 2017

Table 45: Monoclonal Antibodies Market, Breast Cancer, Europe, Revenue ($bn), 2002- 2010

Table 46: Monoclonal Antibodies Market, Breast Cancer, Europe, Revenue Forecasts ($bn), 2010- 2017

Table 47: Monoclonal Antibodies Market, Breast Cancer, ROW, Revenue ($bn), 2002- 2010

Table 48: Monoclonal Antibodies Market, Breast Cancer, ROW, Revenue Forecasts ($bn), 2010- 2017

Table 49: Monoclonal Antibodies Market, HER2 Breast Cancer, Phase lll Molecules, 2011

Table 50: Monoclonal Antibodies Market, HER2 Breast Cancer, Phase ll Molecules, 2011

Table 51: Monoclonal Antibodies Market, HER2 Breast Cancer, Phase l Molecules, 2011

Table 52: Monoclonal Antibodies Market, HER2 Breast Cancer, Preclinical/Discovery Molecules, 2011

Table 53: Monoclonal Antibodies Market, Bone Metastasis, Global, Prescription Population, 2011- 2017

Table 54: Monoclonal Antibodies Market, Bone Metastasis, the US, Prescription Population, 2011- 2017

Table 55: Monoclonal Antibodies Market, Bone Metastasis, Europe, Prescription Population, 2011- 2017

Table 56: Monoclonal Antibodies Market, Bone Metastasis, ROW, Prescription Population, 2011- 2017

Table 57: Monoclonal Antibodies Market, Bone Metastasis, Global, Annual Cost of Therapy ($), 2011- 2017

Table 58: Monoclonal Antibodies Market, Bone Metastasis,The US, Annual Cost of Therapy ($), 2011- 2017

Table 59: Monoclonal Antibodies Market, Bone Metastasis,Europe, Annual Cost of Therapy, 2011- 2017

Table 60: Monoclonal Antibodies Market, Bone Metastasis, ROW, Annual Cost of Therapy ($), 2011- 2017

Table 61: Monoclonal Antibodies Market, Bone Metastasis, Global, Revenue Forecasts ($bn), 2011- 2017

Table 62: Monoclonal Antibodies Market, Bone Metastasis,The US, Revenue Forecasts ($m), 2011- 2017

Table 63: Monoclonal Antibodies Market, Bone Metastasis, Europe, Revenue Forecasts ($m), 2011- 2017

Table 64: Monoclonal Antibodies Market, Bone Metastasis, ROW, Revenue Forecasts ($m), 2011- 2017

Table 65: Monoclonal Antibodies Market, Bone Metastasis, NDA Filed Molecules , 2011

Table 66: Monoclonal Antibodies Market, Bone Metastasis, Phase ll Molecules , 2011

Table 67: Monoclonal Antibodies Market, Bone Metastasis, Phase l Molecules , 2011

Table 68: Monoclonal Antibodies Market, Bone Metastasis, Preclinical/Discovery Molecules , 2011

Table 69: Monoclonal Antibodies Market, RRMS, Global, Prescription Population, 2006- 2010

Table 70: Monoclonal Antibodies Market, RRMS, Global, Prescription Population, 2010- 2017

Table 71: Monoclonal Antibodies Market, RRMS,The US, Prescription Population, 2006- 2010

Table 72: Monoclonal Antibodies Market, RRMS,The US, Prescription Population, 2010- 2017

Table 73: Monoclonal Antibodies Market, RRMS,Europe, Prescription Population, 2006- 2010

Table 74: Monoclonal Antibodies Market, RRMS,Europe, Prescription Population, 2010- 2017

Table 75: Monoclonal Antibodies Market, RRMS, ROW, Prescription Population, 2009- 2010

Table 76: Monoclonal Antibodies Market, RRMS, ROW, Prescription Population, 2010- 2017

Table 77: Monoclonal Antibodies Market, RRMS, Global, Annual Cost of Therapy ($), 2006- 2010

Table 78: Monoclonal Antibodies Market, RRMS, Global, Annual Cost of Therapy ($), 2010- 2017

Table 79: Monoclonal Antibodies Market, RRMS,The US, Annual Cost of Therapy ($), 2006- 2010

Table 80: Monoclonal Antibodies Market, RRMS,The US, Annual Cost of Therapy ($), 2010- 2017

Table 81: Monoclonal Antibodies Market, RRMS,Europe, Annual Cost of Therapy ($), 2006 2010

Table 82: Monoclonal Antibodies Market, RRMS,Europe, Annual Cost of Therapy ($), 2010- 2017

Table 83: Monoclonal Antibodies Market, RRMS, ROW, Annual Cost of Therapy ($), 2006- 2010

Table 84: Monoclonal Antibodies Market, RRMS, ROW, Annual Cost of Therapy ($), 2010- 2017

Table 85: Monoclonal Antibodies Market, RRMS, Global, Revenue ($bn), 2006- 2010

Table 86: Monoclonal Antibodies Market, RRMS, Global, Revenue Forecasts ($bn), 2010- 2017

Table 87: Monoclonal Antibodies Market, RRMS,The US, Revenue ($m), 2006- 2010

Table 88: Monoclonal Antibodies Market, RRMS,The US, Revenue Forecasts ($m), 2010- 2017

Table 89: Monoclonal Antibodies Market, RRMS,Europe, Revenue ($m), 2006- 2010

Table 90: Monoclonal Antibodies Market, RRMS,Europe, Revenue Forecasts ($m), 2010- 2017

Table 91: Monoclonal Antibodies Market, RRMS, ROW, Revenue ($m), 2009- 2010

Table 92: Monoclonal Antibodies Market, RRMS, ROW, Revenue Forecasts ($m), 2010- 2017

Table 93: Monoclonal Antibodies Market, RRMS, Phase lll Molecules, 2011

Table 94: Monoclonal Antibodies Market, RRMS, Phase ll Molecules, 2011

Table 95: Monoclonal Antibodies Market, RRMS, Phase l Molecules, 2011

Table 96: Monoclonal Antibodies Market, RRMS, Preclinical/Discovery Molecules, 2011

Table 97: Monoclonal Antibodies Market, NSCLC, Global, Prescription Population, 2007- 2010

Table 98: Monoclonal Antibodies Market, NSCLC, Global, Prescription Population, 2010- 2017

Table 99: Monoclonal Antibodies Market, NSCLC, The US, Prescription Population, 2007- 2010

Table 100: Monoclonal Antibodies Market, NSCLC, The US, Prescription Population, 2010- 2017

Table 101: Monoclonal Antibodies Market, NSCLC, Europe, Prescription Population, 2008- 2010

Table 102: Monoclonal Antibodies Market, NSCLC, Europe, Prescription Population, 2010- 2017

Table 103: Monoclonal Antibodies Market, NSCLC, ROW, Prescription Population, 2007- 2010

Table 104: Monoclonal Antibodies Market, NSCLC, ROW, Prescription Population, 2010- 2017

Table 105: Monoclonal Antibodies Market, NSCLC, Global, Annual Cost of Therapy ($), 2007- 2010

Table 106: Monoclonal Antibodies Market, NSCLC, Global, Annual Cost of Therapy ($), 2010- 2017

Table 107: Monoclonal Antibodies Market, NSCLC, The US, Annual Cost of Therapy ($), 2007- 2010

Table 108: Monoclonal Antibodies Market, NSCLC, The US, Annual Cost of Therapy ($), 2010- 2017

Table 109: Monoclonal Antibodies Market, NSCLC, Europe, Annual Cost of Therapy ($), 2008- 2010

Table 110: Monoclonal Antibodies Market, NSCLC, Europe, Annual Cost of Therapy ($), 2010- 2017

Table 111: Monoclonal Antibodies Market, NSCLC, ROW, Annual Cost of Therapy ($), 2007- 2010

Table 112: Monoclonal Antibodies Market, NSCLC, ROW, Annual Cost of Therapy ($), 2010- 2017

Table 113: Monoclonal Antibodies Market, NSCLC, Global, Revenue ($bn), 2007- 2010

Table 114: Monoclonal Antibodies Market, NSCLC, Global, Revenue Forecasts ($bn), 2010- 2017

Table 115: Monoclonal Antibodies Market, NSCLC, The US, Revenue ($bn), 2007- 2010

Table 116: Monoclonal Antibodies Market, NSCLC, The US, Revenue Forecasts ($bn), 2010- 2017

Table 117: Monoclonal Antibodies Market, NSCLC, Europe, Revenue ($million), 2008- 2010

Table 118: Monoclonal Antibodies Market, NSCLC, Europe, Revenue Forecasts ($million), 2010- 2017

Table 119: Monoclonal Antibodies Market, NSCLC, ROW, Revenue ($m), 2007- 2010

Table 120: Monoclonal Antibodies Market, NSCLC, ROW, Revenue Forecasts ($m), 2010- 2017

Table 121: Monoclonal Antibodies Market, NSCLC, Phase lll Molecules, 2011

Table 122: Monoclonal Antibodies Market, NSCLC, Phase ll Molecules, 2011

Table 123: Monoclonal Antibodies Market, NSCLC, Phase l Molecules, 2011

Table 124: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Prescription Population, 2002- 2010

Table 125: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Prescription Population, 2010- 2017

Table 126: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Prescription Population, 2002- 2010

Table 127: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Prescription Population, 2010- 2017

Table 128: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Prescription Population, 2002- 2010

Table 129: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Prescription Population, 2010- 2017

Table 130: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Prescription Population, 2002- 2010

Table 131: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Prescription Population, 2010- 2017

Table 132: Monoclonal Antibodies Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2002- 2010

Table 133: Monoclonal Antibodies Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2010- 2017

Table 134: Monoclonal Antibodies Market, Rheumatoid Arthritis, The US, Annual Cost of Therapy ($), 2002- 2010

Table 135: Monoclonal Antibodies Market, Rheumatoid Arthritis, The US, Annual Cost of Therapy ($), 2010- 2017

Table 136: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Annual Cost of Therapy ($), 2002- 2010

Table 137: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Annual Cost of Therapy ($), 2010- 2017

Table 138: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Annual Cost of Therapy ($), 2002- 2010

Table 139: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Annual Cost of Therapy ($), 2010- 2017

Table 140: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Revenue ($bn), 2002- 2010

Table 141: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Revenue Forecasts ($bn), 2010- 2017

Table 142: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Revenue ($bn), 2002- 2010

Table 143: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Revenue Forecasts ($bn), 2010- 2017

Table 144: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Revenue ($m), 2002- 2010

Table 145: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Revenue ($m), 2002- 2010

Table 146: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Revenue ($bn), 2002- 2010

Table 147: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Revenue Forecasts ($bn), 2010- 2017

Table 148: Monoclonal Antibodies Market, Rheumatoid Arthritis, Phase III Molecules, 2011

Table 149: Monoclonal Antibodies Market, Rheumatoid Arthritis, Phase II Molecules, 2011

Table 150: Monoclonal Antibodies Market, Rheumatoid Arthritis, Phase I Molecules, 2011

Table 151: Monoclonal Antibodies Market, Rheumatoid Arthritis, Preclinical/ Discovery Phase Molecules, 2011

Table 152: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010

Table 154: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010

Table 155: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010

Table 156: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010

Table 157: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010

Table 158: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010

Table 159: Monoclonal Antibodies Market, Strategic Consolidations, Top M&A Deals, 2011

Table 153: Monoclonal Antibodies Market, Strategic Consolidations, Licensing Agreement Deals by Value, 2011

Table 161: Monoclonal Antibodies Market, Strategic Consolidations, Partnerships, Analysis by Value, 2011



If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.